Select Page

South Delhi Pharma, New Delhi, India

MULPLETA (lusutrombopag tablets) for oral use

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

MULPLETA is a prescription medicine. MULPLETA is used to treat low platelet count (thrombocytopenia) in adults with chronic liver disease.
INDICATIONS AND USAGE
MULPLETA is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
DOSAGE FORMS & STRENGTHS
Tablet: 3 mg
Manufactured By: Shionogi Inc.
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “MULPLETA (lusutrombopag tablets) for oral use” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

9 + 11 =

Lusutrombopag, sold under the brand name Mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured and marketed in Japan by Shionogi. It was approved by the U.S. Food and Drug Administration (FDA) in July 2018, and NICE in January 2020.

It was approved for medical use in the European Union in February 2019.

Reviews

There are no reviews yet.

Be the first to review “MULPLETA (lusutrombopag tablets) for oral use”

Your email address will not be published.